|Date & Time||25 November 2021 at 10:30-12:30 CET|
On 25 November, the Federation of European Academies of Medicine (FEAM), with the support of Novartis, is hosting a joint activity discussing and examining drug development within the European Union and beyond. Prior to the arrival of any medicine on the market, each product goes through a lengthy research and development process which is tested for safety and efficacy. Stakeholders at all stages in this process have drawn attention to length, complexity, costs, hard to retrieve data for reproduction, a lack of focus on patient needs as well as a disparity between the pace of innovation and regulatory mechanisms.
Therefore, the FEAM’s European Biomedical Policy Forum is organising a public event sponsored by Novartis with the purpose of discussing how this multi-stakeholder network could function more efficiently, identifying challenges and lessons learned to date especially in light of the COVID-19 pandemic. The outcome will be a summary report to inform and empower as cooperation between stakeholders and Member States is vital.
Martin de Kort EATRIS Senior Scientific Programme Manager will be a panellist at the event moderated by Prof George Griffin.
Join this discussion and register for the event here.
Please find the PDF version of the agenda here.
If you have any queries, please contact Elisa Corritore: email@example.com